$MTEM
Molecular Templates, Inc.

2020 Q3 Form 10-Q Financial Statement

#000156459020051635 Filed on November 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q3 2019 Q2
Revenue $4.300M $3.618M $5.447M
YoY Change 18.85% -46.42% 298.46%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.550M $4.510M $4.610M
YoY Change 67.41% 27.4% 23.92%
% of Gross Profit
Research & Development $19.62M $15.25M $10.24M
YoY Change 28.68% 83.94% 33.69%
% of Gross Profit
Depreciation & Amortization $1.200M $500.0K $500.0K
YoY Change 140.0% 25.0% 316.67%
% of Gross Profit
Operating Expenses $27.17M $41.88M $14.85M
YoY Change -35.13% 405.2% 30.47%
Operating Profit -$22.87M -$38.26M -$9.401M
YoY Change -40.23% -6.11%
Interest Expense $167.0K $396.0K $543.0K
YoY Change -57.83% 41.94% 454.08%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$23.23M -$38.22M -$9.153M
YoY Change -39.23% 629.37% -5.64%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$23.23M -$38.22M -$9.153M
YoY Change -39.23% 629.37% -5.59%
Net Earnings / Revenue -540.12% -1056.36% -168.04%
Basic Earnings Per Share
Diluted Earnings Per Share -$473.8K -$1.035M -$248.5K
COMMON SHARES
Basic Shares Outstanding 36.94M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $116.2M $51.40M $72.32M
YoY Change 126.07% -34.69% 73.86%
Cash & Equivalents $33.41M $15.27M $16.80M
Short-Term Investments $82.80M $36.10M $55.53M
Other Short-Term Assets $9.600M $300.0K $98.00K
YoY Change 3100.0% -95.65% -94.84%
Inventory
Prepaid Expenses $2.258M
Receivables $300.0K $0.00 $0.00
Other Receivables $3.500M $5.600M $5.200M
Total Short-Term Assets $129.7M $64.15M $79.84M
YoY Change 102.19% -45.08% 80.63%
LONG-TERM ASSETS
Property, Plant & Equipment $20.89M $13.88M $9.151M
YoY Change 50.45% 92.83% 27.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $2.000M
YoY Change
Other Assets $5.200M $4.735M $4.737M
YoY Change 9.82% 264.23% 238.36%
Total Long-Term Assets $39.70M $29.02M $51.31M
YoY Change 36.82% -17.57% 45.76%
TOTAL ASSETS
Total Short-Term Assets $129.7M $64.15M $79.84M
Total Long-Term Assets $39.70M $29.02M $51.31M
Total Assets $169.4M $93.16M $131.1M
YoY Change 81.83% -38.71% 65.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.600M $1.414M $2.577M
YoY Change 83.88% -11.63% 98.23%
Accrued Expenses $13.23M $9.105M $7.120M
YoY Change 45.32% 37.95% 14.84%
Deferred Revenue $11.96M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $0.00
YoY Change
Total Short-Term Liabilities $40.40M $24.10M $25.69M
YoY Change 67.65% -42.21% 93.18%
LONG-TERM LIABILITIES
Long-Term Debt $14.80M $3.001M $3.075M
YoY Change 393.17% -4.88% -0.81%
Other Long-Term Liabilities $29.70M $1.238M $748.0K
YoY Change 2299.03% 46.68% -16.89%
Total Long-Term Liabilities $44.50M $4.239M $3.823M
YoY Change 949.78% 6.0% -4.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $40.40M $24.10M $25.69M
Total Long-Term Liabilities $44.50M $4.239M $3.823M
Total Liabilities $84.90M $40.15M $41.89M
YoY Change 111.48% -12.34% 143.53%
SHAREHOLDERS EQUITY
Retained Earnings -$148.2M -$110.0M
YoY Change
Common Stock $201.2M $199.3M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $84.44M $53.02M $89.26M
YoY Change
Total Liabilities & Shareholders Equity $169.4M $93.16M $131.1M
YoY Change 81.83% -38.71% 65.17%

Cashflow Statement

Concept 2020 Q3 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income -$23.23M -$38.22M -$9.153M
YoY Change -39.23% 629.37% -5.59%
Depreciation, Depletion And Amortization $1.200M $500.0K $500.0K
YoY Change 140.0% 25.0% 316.67%
Cash From Operating Activities -$19.82M -$16.39M -$11.90M
YoY Change 20.93% 68.62% 130.62%
INVESTING ACTIVITIES
Capital Expenditures -$1.080M -$5.210M -$490.0K
YoY Change -79.27% 323.58% -80.16%
Acquisitions
YoY Change
Other Investing Activities -$21.51M $19.59M -$9.470M
YoY Change -209.8%
Cash From Investing Activities -$22.59M $14.39M -$9.970M
YoY Change -256.98% -1269.92% 303.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 48.62M 480.0K 810.0K
YoY Change 10029.17% -99.0% -8200.0%
NET CHANGE
Cash From Operating Activities -19.82M -16.39M -11.90M
Cash From Investing Activities -22.59M 14.39M -9.970M
Cash From Financing Activities 48.62M 480.0K 810.0K
Net Change In Cash 6.210M -1.520M -21.06M
YoY Change -508.55% -104.1% 175.65%
FREE CASH FLOW
Cash From Operating Activities -$19.82M -$16.39M -$11.90M
Capital Expenditures -$1.080M -$5.210M -$490.0K
Free Cash Flow -$18.74M -$11.18M -$11.41M
YoY Change 67.62% 31.68% 324.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsMember
CY2019Q3 us-gaap Restricted Cash And Cash Equivalents Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsMember
CY2020Q3 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:PropertyPlantAndEquipmentNet
CY2020Q3 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y3M18D
CY2020Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3M18D
CY2020Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
0
CY2020Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
0
CY2020Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
0
CY2020Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0
CY2020Q3 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
0
CY2020Q3 us-gaap Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
0
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y1M6D
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38219000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-76471000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-53540000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23225000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
88451000
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
112823000
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
2000000
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
114823000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
114896000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
123977000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-38263000
us-gaap Operating Income Loss
OperatingIncomeLoss
-74925000
us-gaap Operating Income Loss
OperatingIncomeLoss
-54045000
CY2020Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
167000
CY2019Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
396000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
925000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1449000
CY2020Q3 mtem Interest And Other Expense Net
InterestAndOtherExpenseNet
521000
CY2019Q3 mtem Interest And Other Expense Net
InterestAndOtherExpenseNet
353000
mtem Interest And Other Expense Net
InterestAndOtherExpenseNet
1229000
mtem Interest And Other Expense Net
InterestAndOtherExpenseNet
947000
CY2020Q3 mtem Loss On Impairment Of In Process Research And Development
LossOnImpairmentOfInProcessResearchAndDevelopment
0
CY2019Q3 mtem Loss On Impairment Of In Process Research And Development
LossOnImpairmentOfInProcessResearchAndDevelopment
22123000
mtem Loss On Impairment Of In Process Research And Development
LossOnImpairmentOfInProcessResearchAndDevelopment
0
mtem Loss On Impairment Of In Process Research And Development
LossOnImpairmentOfInProcessResearchAndDevelopment
22123000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
27169000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
41881000
us-gaap Operating Expenses
OperatingExpenses
90273000
us-gaap Operating Expenses
OperatingExpenses
70118000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22871000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38219000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-76471000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23225000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2571000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
96000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-107000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-76416000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53520000
CY2020Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2019Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1237000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2020Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2019Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23225000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38219000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-76466000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-53540000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-23225000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-38219000
us-gaap Net Income Loss
NetIncomeLoss
-76471000
us-gaap Net Income Loss
NetIncomeLoss
-53540000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.47
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.03
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.63
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.45
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49026499
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36937912
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
46808437
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36832966
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-99000
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-53540000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
55000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
20000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23324000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38224000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
5176000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
930000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1300000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48372000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
89260000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
103028000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
100906000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
84441000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
53016000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
84441000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
53016000
us-gaap Net Income Loss
NetIncomeLoss
-76471000
us-gaap Net Income Loss
NetIncomeLoss
-53540000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2526000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
628000
us-gaap Share Based Compensation
ShareBasedCompensation
8527000
us-gaap Share Based Compensation
ShareBasedCompensation
4330000
mtem Interest Accrued Paid On Long Term Debt
InterestAccruedPaidOnLongTermDebt
106000
mtem Interest Accrued Paid On Long Term Debt
InterestAccruedPaidOnLongTermDebt
0
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
344000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
347000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3000
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
93000
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
48000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1237000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
22139000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-240000
mtem Increase Decrease In Grants Revenue Receivable
IncreaseDecreaseInGrantsRevenueReceivable
-3610000
mtem Increase Decrease In Collaboration Revenue
IncreaseDecreaseInCollaborationRevenue
-7174000
mtem Increase Decrease In Collaboration Revenue
IncreaseDecreaseInCollaborationRevenue
0
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
115895000
mtem Payments Of Capital And Financing Lease Obligations
PaymentsOfCapitalAndFinancingLeaseObligations
16000
mtem Payments Of Capital And Financing Lease Obligations
PaymentsOfCapitalAndFinancingLeaseObligations
-23000
mtem Proceeds From Issuance Of Long Term Debt And Warrants Net
ProceedsFromIssuanceOfLongTermDebtAndWarrantsNet
14677000
mtem Proceeds From Issuance Of Long Term Debt And Warrants Net
ProceedsFromIssuanceOfLongTermDebtAndWarrantsNet
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
58787000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1323000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-51373000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-69453000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
87721000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33410000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15268000
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3668000
CY2019Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3000000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
37078000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18268000
us-gaap Interest Paid Net
InterestPaidNet
611000
us-gaap Interest Paid Net
InterestPaidNet
514000
mtem Fixed Asset Additions In Accounts Payable And Accrued Expenses
FixedAssetAdditionsInAccountsPayableAndAccruedExpenses
967000
mtem Fixed Asset Additions In Accounts Payable And Accrued Expenses
FixedAssetAdditionsInAccountsPayableAndAccruedExpenses
1197000
mtem Noncash Investing And Financing Activities
NoncashInvestingAndFinancingActivities
967000
mtem Increase Decrease In Grants Revenue Receivable
IncreaseDecreaseInGrantsRevenueReceivable
1262000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-301000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
145000
mtem Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
-129000
mtem Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
566000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
644000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
524000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1930000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2661000
mtem Increase Decrease In Other Noncurrent Liabilities Related Parties
IncreaseDecreaseInOtherNoncurrentLiabilitiesRelatedParties
12209000
mtem Increase Decrease In Other Noncurrent Liabilities Related Parties
IncreaseDecreaseInOtherNoncurrentLiabilitiesRelatedParties
0
mtem Increase Decrease In Deferred Revenue Related Parties Current
IncreaseDecreaseInDeferredRevenueRelatedPartiesCurrent
-3720000
mtem Increase Decrease In Deferred Revenue Related Parties Current
IncreaseDecreaseInDeferredRevenueRelatedPartiesCurrent
-15709000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-62291000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39272000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4512000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6329000
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
15000
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
0
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
73758000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
72523000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
48583000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-47869000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-31504000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
37078000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18268000
mtem Noncash Investing And Financing Activities
NoncashInvestingAndFinancingActivities
1197000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain amounts in the prior year’s presentation have been reclassified to conform to the current presentation. The condensed consolidated balance sheet at December 31, 2019 included herein was derived from the audited financial statements at that date, but includes a reclassification of $8.8 million from Deferred revenue, current to Deferred revenue, current, related party and $0.4 million from Deferred revenue, non-current to Deferred revenue, non-current, related party in order to conform to current period presentation. The condensed consolidated statements of cash flow for the nine months ended September 30, 2019, included herein includes a reclassification of $12.7 million from Deferred revenue to Deferred revenue, related party. </p>
CY2019Q4 mtem Deferred Revenue Related Parties Current
DeferredRevenueRelatedPartiesCurrent
8800000
CY2019Q4 mtem Deferred Revenue Related Parties Noncurrent
DeferredRevenueRelatedPartiesNoncurrent
400000
mtem Reclassification Of Deferred Revenue To Related Party Deferred Revenue
ReclassificationOfDeferredRevenueToRelatedPartyDeferredRevenue
12700000
CY2020Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
118200000
CY2020Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
82816000
CY2020Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
2000000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
39633000
CY2019Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1510000
mtem Research And Development Revenues From Collaboration Agreements
ResearchAndDevelopmentRevenuesFromCollaborationAgreements
14811000
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
125505000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash and cash equivalents, investments, long term debt and accounts receivable.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s cash and cash equivalents are with two major financial institutions in the United States. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company performs an ongoing credit evaluation of its strategic partners’ financial conditions and generally does not require collateral to secure accounts receivable from its strategic partners. The Company’s exposure to credit risk associated with non-payment will be affected principally by conditions or occurrences within Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Ltd. (“Takeda”) and <span style="Background-color:#FFFFFF;color:#000000;">Vertex Pharmaceuticals Incorporated (“Vertex”)</span>. Takeda accounted for approximately 36% and 80% of total revenues for the three months ended September 30, 2020 and September 30, 2019 respectively and approximately 32% and 90% of the total revenues for the nine months ended September 30, 2020 and September 30, 2019, respectively. Vertex accounted for approximately 64% and 0% of total revenues for the three months ended September 30, 2020 and September 30, 2019, respectively and approximately 47% and 0% for the nine months ended September 30, 2020 and September 30, 2019, respectively.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In <span style="color:#000000;">July 2020, the Company became aware of one potentially non-conforming batch of a single Company product fill, which may not meet manufacturing specifications. The Company continues to investigate the batch. The Company continues to investigate the batch. If upon the conclusion of the batch evaluation such batch is deemed to be non-conforming this could result in a reversal of revenue in future periods as the Company recognizes collaboration revenue over time by measuring </span>progress<span style="color:#000000;"> toward completion to satisfy the performance obligation. The Company does not believe this potential non-conforming batch will result in an increased timeline for its ongoing projects nor does it affect any other batches, production, or manufacturing. The Company expects to be able to meet the supply needs for all of its active clinical trials. </span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug or biologic candidates developed by the Company may require approvals or clearances from the U.S. Food and Drug Administration (“FDA”) or international regulatory agencies prior to commercial sales. There can be no assurance that the Company’s drug or biologic candidates will receive any of the required approvals or clearances. If the Company were to be denied approval or clearance or any such approval or clearance were to be delayed, it would have a material adverse impact on the Company.</p>
CY2020Q3 mtem Research And Development Revenues From Collaboration Agreements
ResearchAndDevelopmentRevenuesFromCollaborationAgreements
4298000
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
112896000
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
2000000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
123995000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
1510000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
1510000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
125487000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
125505000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
1300000
CY2020Q3 mtem Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
1648000
CY2019Q4 mtem Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
4521000
CY2020Q3 mtem Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
2932000
CY2019Q4 mtem Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
1383000
CY2020Q3 mtem Accrued Non Clinical Research And Manufacturing Operations Current
AccruedNonClinicalResearchAndManufacturingOperationsCurrent
4674000
CY2019Q4 mtem Accrued Non Clinical Research And Manufacturing Operations Current
AccruedNonClinicalResearchAndManufacturingOperationsCurrent
5774000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3924000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2849000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
53000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
17000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13231000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14544000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
0
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
671000
us-gaap Operating Lease Cost
OperatingLeaseCost
1794000
CY2020Q3 us-gaap Variable Lease Cost
VariableLeaseCost
124000
us-gaap Variable Lease Cost
VariableLeaseCost
369000
CY2020Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
795000
us-gaap Operating Lease Expense
OperatingLeaseExpense
2163000
CY2020Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2000
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
26904000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21451000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6015000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3293000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20889000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18158000
CY2020Q3 us-gaap Depreciation
Depreciation
1200000
CY2019Q3 us-gaap Depreciation
Depreciation
500000
us-gaap Depreciation
Depreciation
2700000
us-gaap Depreciation
Depreciation
1300000
CY2020Q3 us-gaap Long Term Debt
LongTermDebt
14800000
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
3700000
CY2020Q3 mtem Finance Lease Expense
FinanceLeaseExpense
2000
mtem Finance Lease Expense
FinanceLeaseExpense
6000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11589000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2038000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12828000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
14866000
CY2020Q3 us-gaap Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
77000
CY2020Q3 mtem Finance Lease Right Of Use Asset Accumulated Depreciation
FinanceLeaseRightOfUseAssetAccumulatedDepreciation
47000
CY2020Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
30000
CY2020Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
3000
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0703
CY2020Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0651
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
683000
CY2020Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
3000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3155000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3361000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2689000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2218000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2147000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
4246000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
18499000
CY2020Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
3000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3633000
CY2020Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
0
CY2020Q3 mtem Lessee Operating Lease Liability Total Lease Payments Net Of Interest
LesseeOperatingLeaseLiabilityTotalLeasePaymentsNetOfInterest
14866000
CY2020Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
3000
us-gaap Operating Lease Payments
OperatingLeasePayments
1771000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
1000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
16000
CY2020Q3 mtem Upfront Fees Unamortized Balance Included In Prepaid Asset
UpfrontFeesUnamortizedBalanceIncludedInPrepaidAsset
1300000
CY2020Q3 us-gaap Contractual Obligation
ContractualObligation
16400000
mtem Development Costs Sharing Percentage Exercised
DevelopmentCostsSharingPercentageExercised
0.50
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3285000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1527000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8527000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4330000
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
33900000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4763062
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.36
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
36600000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2374006
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.23
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
240659
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.87
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
104436
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.12
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6791973
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.12
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
20500000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2554485
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.47
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
11900000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2400000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
900000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1300000
mtem Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options1
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions1
0
mtem Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options1
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions1
0
CY2019 mtem Impairment Of Long Lived Assets Held For Sale
ImpairmentOfLongLivedAssetsHeldForSale
22100000
CY2019Q4 mtem In Process Research And Development Held For Sale Current
InProcessResearchAndDevelopmentHeldForSaleCurrent
4500000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
300000000.0

Files In Submission

Name View Source Status
0001564590-20-051635-index-headers.html Edgar Link pending
0001564590-20-051635-index.html Edgar Link pending
0001564590-20-051635.txt Edgar Link pending
0001564590-20-051635-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mtem-10q_20200930.htm Edgar Link pending
mtem-10q_20200930_htm.xml Edgar Link completed
mtem-20200930.xsd Edgar Link pending
mtem-20200930_cal.xml Edgar Link unprocessable
mtem-20200930_def.xml Edgar Link unprocessable
mtem-20200930_lab.xml Edgar Link unprocessable
mtem-20200930_pre.xml Edgar Link unprocessable
mtem-ex311_7.htm Edgar Link pending
mtem-ex312_6.htm Edgar Link pending
mtem-ex321_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending